0001179110-17-011284.txt : 20170809
0001179110-17-011284.hdr.sgml : 20170809
20170809163201
ACCESSION NUMBER: 0001179110-17-011284
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170808
FILED AS OF DATE: 20170809
DATE AS OF CHANGE: 20170809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Ravindra
CENTRAL INDEX KEY: 0001586835
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 171018358
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2017-08-08
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586835
Kumar Ravindra
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP & Chief Scientific Officer
Common Stock
2017-08-08
4
M
0
13065
24.11
A
108392
D
Common Stock
2017-08-08
4
S
0
13065
35.41
D
95327
D
Option to Purchase Common Stock
24.11
2017-08-08
4
M
0
13065
0
D
2023-12-05
Common Stock
13065
3624
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
/s/ John D. Quisel, as attorney-in-fact for Ravindra Kumar
2017-08-09